Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidaza in older patients with newly diagnosed AML
NCT01074047Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2010
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Jun 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01074047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01074047.